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From the aerial parts of Geranium pyrenaicum Burm., a new flavonol glycoside, kaempferol 3-O00

(2 ,300 -di-O-galloyl)-ß -D-glucopyranoside (7), along with 6 known related glycosides [kaempferol 3-Oß -D-glucopyranoside (1), quercetin 3-O-ß -D-glucopyranoside (2), quercetin 3-O-ß -D-galactopyranoside
(3), kaempferol 3-O-(200 -O-galloyl)-ß -D-glucopyranoside (4), quercetin 3-O-(200 -O-galloyl)-ß -D-glucopyranoside (5) and quercetin 3-O-(200 ,300 -di-O-galloyl)-ß -D-glucopyranoside (6)] and the ellagitannins corilagin (8) and tellimagrandin I (9) were isolated. Their structures were established from spectroscopic
studies (UV, FAB-MS, 1 H and

13

C-NMR, 1 H-1 H COSY, HETCOR, HMBC). Compounds 1-7 were eval-

uated for antileishmanial activity against a panel of Leishmania species (L. major, L. donovani and L.
amazonensis), indicating appreciable in vitro activities (IC50 4-27 nM) when compared with Pentostam
(IC50 10-11 nM).
Key Words: Geranium pyrenaicum, Geraniaceae, Flavonoids, Ellagitannins, Antileishmanial activity.

Introduction
The genus Geranium (Geraniaceae),which includes about 400 species distributed throughout the temperate
regions, is chemically characterized by the presence of tannins, flavonoids, anthocyanins and essential oils1 .
The aerial parts of some Geranium species, known as “Turnagagasi”, have been employed as a tonic, diuretic,
antidiabetic, antidiarrheal and antihemorrhoidal as well as a remedy to treat gastric disorders and to promote
the healing of wounds2 . Despite these medicinal facets, detailed studies on the polyphenolic constituents
of Geranium species are limited. Among the traditionally used Geranium species2 G. pyrenaicum Burm.
is widespread in the central parts of Turkey3 . No chemical investigation on this species has so far been
∗ Corresponding

author
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reported. This paper reports on the isolation and structure elucidation of a series of flavonoids (1-7) (Figure
1), including a new (7) and a rarely found analogue (6), associated with the known ellagitannins corilagin
(8) and tellimagrandin I (9) from this plant source.
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(4) R1 = H; R2 = galloyl; R3 = H
(5) R1 = OH; R2 = galloyl; R3 = H
(6) R1 = OH; R2 = R3 = galloyl
(7) R1 = H; R2 = R3 = galloyl
Figure 1. Isolated compounds 1-7.

Leishmaniasis is a major health problem in most developing countries, but it is beginning to have
a major impact on human populations in the developed world as well. In Turkey, cutaneous leishmaniasis
and sporadic cases of the visceral form are reported4,5 . Continuing our research program to identify new
antileishmanial candidates, compounds 1-7 were tested for activity against a panel of Leishmania parasites.

Experimental
General Experimental Procedures:

1

H and

13

C NMR spectra were recorded on a Bruker DPX-400

instrument and chemical shifts are given in δ (ppm) relative to (Me)4 Si. HMBC experiments were optimized
for

2−3

JH/C = 10 Hz. EI- and FAB-mass spectra were obtained on a Varian MAT CH7 A and Finnigan

MAT CH5 DF mass spectrometer, respectively. UV spectra were recorded on a Shimadzu UV160-A model.
For prep. TLC, glass supported silica gel plates (0.25 mm layer, 60 F254 , Merck) were used and Sephadex
LH-20 (Fluka) was employed for column chromatography. Compounds were visualized by exposure to UV
(254 nm) and then spraying with FeCl3 and Naturstoffreagenz A.
Plant Material: The aerial parts of Geranium pyrenaicum were collected from Kızılcahamam, near
Ankara, Turkey, in June 2000. A voucher specimen has been deposited in the Herbarium of the Faculty of
Pharmacy, Hacettepe University, Ankara (HUEF 00170).
Extraction and Isolation: The dried and powdered aerial parts of G. pyrenaicum (800 g) were
defatted with petroleum ether (40-60 o C) (2.5 L x 3) and then extracted with 20% aqueous methanol (2 L
x 3). The combined extracts were reduced in volume and then successively treated with n-hexane (200 mL
x 4), EtOAc (200 mL x 4) and 1-BuOH (200 mL x 4).
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The ethyl acetate soluble portion (4 g) was initially chromatographed on Sephadex LH-20 (3 x 50 cm)
with gradient solvent systems of MeOH-H2 O (1:9→1:0) to afford 26 crude subfractions (E 1-E 26). Following
qualitative TLC analysis on silica gel (EtOAc:formic acid:H2 O; 18:1:1) appropriate fractions (20 mL) were
combined and further resolved by preparative TLC.
Preparative TLC separation of the subfractions E 11 (10% MeOH; 30 mg), E 14 (15% MeOH; 50 mg),
E 21 (40% MeOH; 40 mg) and E 24 (60% MeOH; 110 mg) was performed using EtOAc-MeOH-H2 O-HOAc
(17:1:0.5:1.5) as a developing system to yield compounds 2 (6 mg) and 3 (12 mg), 5 (23 mg), 8 (2 mg),
and 9 (35 mg), respectively. Preparative TLC purification of E 12 (10% MeOH; 240 mg) with CHCl3 MeOH-H2 O (65:25:4) afforded compound 1 (15 mg), while E 20 (25% MeOH; 90 mg) using the same mobile
system gave compound 4 (28 mg). Similar preparative TLC purification of E 25 (60% MeOH; 300 mg) using
CHCl3 -MeOH-H2 O (61:32:7) as the mobile phase afforded compounds 6 (77 mg) and 7 (25 mg).
Quercetin 3-O-(200, 300 -di-O-galloyl)-β-D-glucopyranoside (6): Amorphous powder. Rf 0.67;
CHCl3 -MeOH-H2 O (61:32:7); pos. FAB-MS: m/z 791 [M+Na]+ ; 769 [M+H]+ ; 616 [M-Gallic acid+H]+ ;
463 [M-Gallic acid-Gallic acid+H]+ ; 303 [M-Gallic acid-Gallic acid-Glucose+H]+ . 1 H NMR (CD3 OD): 3.49
(ddd, J =2.0, 5.0, 9.4; H-500 ), 3.69 (dd, J =5.0, 12.0; Ha -600 ), 3.80 (dd, J =9.0, 9.4; H-400 ), 3.84 (dd, J =2.0,
12.0; Hb -600 ), 5.35 (dd, J =7.3, 9.50; H-200 ), 5.38 (dd, J =9.0, 9.5; H-300 ), 5.77 (d, J =7.3; H-100 ), 6.10 (d, J
=1.9; H-6), 6.24 (d, J =1.9; H-8), 6.77 (d, J =8.5; H-50 ), 6.96 (s, H-20000), 6.96 (s, H-60000), 7.00 (s, H-2000 ),
7.00 (s, H-6000), 7.45 (dd, J =2.0, 8.5; H-60 ), 7.50 (d, J =2.0; H-20 ).

13

C NMR: 62.21 (C-600 ), 69.64 (C-400 ),

74.07 (C-200 ), 77.11 (C-300 ), 78.75 (C-500 ), 95.23 (C-8), 100.65 (C-6), 100.65 (C-100), 105.20 (C-10), 110.44
(C-20000 ), 110.44 (C-60000), 110.60 (C-2000 ), 110.60 (C-6000 ), 116.27 (C-50 ), 116.94 (C-20 ), 120.64 (C-1000), 120.91
(C-10000 ), 122.99 (C-10 ), 123.35 (C-60 ), 134.92 (C-3), 140.31 (C-40000), 140.40 (C-4000 ), 146.20 (C-30 ), 146.33
(C-30000 ), 146.33 (C-50000), 146.42 (C-3000 ), 146.42 (C-5000), 150.03 (C-40 ), 158.02 (C-2), 158.56 (C-9), 163.09
(C-5), 167.34 (C-7), 167.96 (C-7000 ), 167.96 (C-70000), 178.86 (C-4).
Kaempferol 3-O-(200, 300 -di-O-galloyl)-β-D-glucopyranoside (7): Amorphous powder. Rf
0.71; CHCl3 -MeOH-H2 O (61:32:7); UV λmax (MeOH) nm: 269, 292(sh); pos. FAB-MS: m/z 775 [M+Na]+ ;
753 [M+H]+ ; 601 [M-Gallic acid+H]+ ; 447 [M-Gallic acid-Gallic acid+H]+ ; 287 [M-Gallic acid-Gallic acidGlucose+H]+ . 1 H NMR (CD3 OD): 3.47 (ddd, J =2.0, 5.0, 9.5; H-500 ), 3.66 (dd, J = 5.0, 12.0; Ha -600 ), 3.77
(dd, J =9.0, 9.5; H-400 ), 3.81 (dd, J =2.0, 12.0; Hb -600), 5.31 (dd, J =7.5, 9.5; H-200 ), 5.36 (dd, J =9.0, 9.50;
H-300 ), 5.74 (d, J =7.5; H-100 ), 6.08 (d, J =1.9; H-6), 6.22 (d, J =1.9; H-8), 6.80 (d, J =8.8; H-30 ), 6.80 (d, J
=8.8; H-50 ), 6.96 (s, H-20000), 6.96 (s, H-60000), 7.00 (s, H-2000), 7.00 (s, H-6000 ), 7.87 (d, J =8.8; H-20 ), 7.87 (d, J
=8.8; H-60 ).

13

C NMR: 60.13 (C-600 ), 71.86 (C-400 ), 74.76 (C-200 ), 77.32 (C-300 ), 79.06 (C-500 ), 94.02 (C-8),

97.80 (C-100 ), 99.77 (C-6), 102.36 (C-10), 108.56 (C-20000), 108.56 (C-60000), 108.66 (C-2000), 108.66 (C-6000 ),
115.17 (C-30 ), 115.17 (C-50 ), 117.49 (C-1000), 118.09 (C-10000), 120.53 (C-10 ), 130.60 (C-20 ), 130.60 (C-60 ),
131.96 (C-3), 139.51 (C-40000), 139.91 (C-4000), 145.39 (C-3000 ), 145.39 (C-5000 ), 145.39 (C-30000), 145.39 (C-50000),
155.25 (C-2), 156.54 (C-9), 160.11 (C-40 ), 160.92 (C-5), 164.82 (C-7), 164.82 (C-7000), 165.11 (C-70000), 176.19
(C-4).
Assay for leishmanicidal activity: Assays for leishmanicidal activity and cytokine (TNF, IFN-γ
and IL-6) inducing potentials were performed as described previously6,7 .
For testing the immunomodulatory activities of the compounds, murine macrophage-like RAW246.7
cells were infected with L. major, L. donovani and L. amazonensis. Then the cells were treated with the
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compounds. After lysis of the cells, survival of leishmania was detected. In the following step, 5 x 106 cells
(infected and non-infected control) were treated with the compounds in their IC50 concentration, and after
24 h the supernatants were collected for cytokine measurement using cell lines cytokine-sensitive (L929TNF, L929-IFN and B9-IL6) and ELISA specific for IFN-α and IFN-γ. Direct toxicity against promastigote
leishmania and RAW cells was observed in parallel. Pentostamr was used for comparison as a standard
drug of antileishmanial activity6,7.

Results and Discussion
An aqueous methanol extract of the dried aerial parts of G. pyrenaicum was successively treated with nhexane, ethyl acetate and 1-butanol. The ethyl acetate soluble portion was chromatographed on Sephadex
LH-20 using a water-methanol gradient system. Subsequent preparative TLC separations afforded a series of
flavonoid glycosides (1-7) along with the ellagitannins corilagin (8)8 and tellimagrandin I (9)9 . Known compounds amongst the flavonoid metabolites included kaempferol 3-O-β-D-glucopyranoside (1)10 , quercetin 3O-β-D-glucopyranoside (2)10 , quercetin 3-O-β-D-galactopyranoside (3)11 , kaempferol 3-O-(200 -O-galloyl)-βD-glucopyranoside (4)12 , quercetin 3-O-(200 -O-galloyl)-β-D-glucopyranoside (5)13 , and quercetin 3-O-(200, 300 di-O-galloyl)-β-D-glucopyranoside (6)14 , which were readily identified by comparison of the physical properties with those reported in the literature13,14 . Noteworthy is the fact that compound 6 represents a
rarely found metabolite, its occurrence being hitherto confined to a single plant source, Euphorbia maculata
L.14 . Since the NMR spectral data of 6 were previously recorded in acetone-d4 /D2 O, these are included for
comparative purposes (see Experimental).
Compound 7, a yellow amorphous powder, exhibited a pseudomolecular ion peak at m/z 753 in the
positive FAB mass spectrum, consistent with a molecular formula of C35 H28 O19 , and the sodium adduct
[M+Na]+ peak at m/z 775. The ion peak at m/z 775 yields a product ion at m/z 601 corresponding to
cleavage of a single gallic acid bond and an ion peak at m/z 447 corresponding to cleavage of 2 gallic acid
moieties. Subsequently an ion peak of m/z 287 corresponds to a loss of 2 gallic acids and glucose moieties.
Analysis of the 1 H NMR spectrum of 7 revealed the presence of meta-coupling protons (δ 6.08 and 6.22,
each d, J=1.9 Hz, H-6 and H-8, respectively) and an AA0 BB0 -spin system for the aromatic A- and B-ring
protons (δ 6.80 and 7.87), respectively10 . The 1 H NMR spectrum also displayed an anomeric proton signal
at δ 5.74 arising from a β-D-glucopyranosyl moiety (J1 00 2 00 = 7.5 Hz). The anomeric proton of glucose (δ
5.74) was seen further downfield than that of kaempferol 3-O-ß-D-glucopyranoside (δ 5.22) because of the
esterification of glucose moiety15. Notable differences included the appearance of 2 sharp low-field 2-proton
singlets at δ 6.96 and 7.00 for the magnetically equivalent 2- and 6-protons of 2 galloyl groups and the
conspicuous deshielding of 200 -H and 300 -H of the glycosyl residue (∆δ 1.86 and 1.95, respectively) relative
to their chemical shifts in the non-galloylated analogue of kaempferol 3-O-β-D-glucopyranoside (1), clearly
indicating that the hydroxyl groups at these positions were acylated. Independent support for the location
of the galloyl groups at C-2 and C-3 of the carbohydrate moiety was also available from a comparison of
the

13

C NMR data of 7 with those of 1 and its monogalloylated analogue 4. The position of sugar residue

and galloyl moieties were unambiguously determined by the HMBC experiment (Figure 2). Long-range
correlations observed in the HMBC spectrum from H-100 to C-3, and from H-200 and H-300 to the carbonyl
carbons at δ 164.82 and δ 165.11, respectively, established the points of attachment of both galloyl moieties
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to the carbohydrate residue. These spectral features defined compound 7 as a new kaempferol 3-O-(200, 300 di-O-galloyl)-β-D-glucopyranoside.
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Figure 2. Selected HMBC correlations for compound 7. Arrows point from H to C.

The characterization of compound 7 not only extends the range of natural O-galloylflavonoids but also
introduces the first example of a 200 , 300-diacylated kaempferol derivative in this group of secondary products.
Antileishmanial Activity: The antileishmanial activity of compounds 1-7 was assessed against
both extracellular promastigotes and intracellular amastigotes of a panel of Leishmania species (Table),
with L. major and L. donovani as causative agents of Old World cutaneous and visceral leishmaniasis,
respectively. As a parameter for antileishmanial activity, the IC 50 value, i.e. the sample concentration
causing a 50% reduction in survival/viability of the parasites, was used. None of the samples showed
selective toxicity when tested against the promastigote stages of the 3 Leishmania species (IC50 > 0.4 µM).
In contrast, all compounds tested reduced the intracellular survival of Leishmania amastigotes within RAW
264.7 cells (IC50 4–27 nM) in our in vitro experiments, when compared with the IC50 values, 10.1–10.6 nM,
of the therapeutically used antileishmanial drug Pentostamr. Notably, all samples appeared to be non-toxic
against the host cells (IC50 > 0.5 µM).
Concerning structure-activity relationships, the presence of galloyl groups dramatically decreased the
antileishmanial potency, at least in the series of quercetin derivatives (2, 3, 5, and 6). For the kaempferol
analogues (1, 4, and 7), no clear correlations were obvious. This phenomenon cannot be satisfactorily
explained at present.
Tumor necrosis factor (TNF)-α, produced principally by activated macrophages and monocytes, plays
a crucial role in the host defense against various pathogens16 . As shown in the Table, the amounts of TNF
induced by the tested flavonoids 1-7 in non-parasitized RAW 264.7 were below the detection limit. In
contrast, all samples induced moderate (9-90 U/mL for 2-6) or significant TNF release (204-270 U/mL
for 1) in Leishmania-parasitized RAW 264.7 cells compared to IFN-γ + LPS as a positive control (197-210
U/mL). The considerable TNF-inducing potential of 1 cannot be explained on the basis of structure-activity
relationships. Importantly, all test compounds were first subjected to assays for endotoxin contamination
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(Limulus amoebocyte lysate method), which may stimulate immune cells, of which we found no evidence.
Macrophage functions are intimately related to the IFN system producing not only IFN-α but also,
at least under certain conditions, IFN-γ 17 . Accordingly, attention was given to possible IFN-like activities
induced by flavonoid glycosides in RAW cells. For this, supernatants of sample-activated RAW cells were
analyzed for their capacity to protect L929 cells from the cytopathic effect of encephalomyocarditis virus
(EMCV). The relative number of protected, i.e. viable cells, was determined spectrophotometrically using
crystal violet as staining reagent. Medium alone served as a negative and a recombinant murine IFN-γ (100
U/mL) as a positive control for cytoprotection. The IFN-like activities found in supernatants of sampletreated infected RAW cells ranged from negligible to moderate (4-42 U/mL) (Table).
Keeping in mind the essential role of IL-6 in the proliferation and differentiation of immune cells18 ,
this factor was assessed in a functional bioassay employing the selective dependency of murine B9 hybridoma
cells on IL-6 for survival and proliferation19. Appropriate controls were performed using medium alone for
minimal and a defined laboratory IL-6 standard (70 U/mL) for maximal cell proliferation. The results listed
in the Table show that all compounds stimulated RAW 264.7 cells to some extent for IL-6 release. Of
the series of flavonoid glycosides tested, compound 1 activated Leishmania-parasitized RAW 264.7 cells to
release more IL-6 (25-33 U/mL) than the stimulus IFN-γ/ LPS (7-12 U/mL) alone, whereas the remaining
compounds exhibited only marginal inducing potentials (2-7 U/mL). As with TNF and IFN, the activation
of non-parasitized cells was below detection limits.
Previously structure-activity relationship studies have been performed on some other flavonoids (the
chalcones, aurones and flavon-3-ol derivatives). However, the results studies cannot be compared with ours,
because their substances are not structurally similar to 1-720−22.
The present results provide evidence that flavonoid glycosides possess the capability to stimulate
defense mechanisms in Leishmania-infected RAW 264.7 cells, albeit with moderate potential. Although
distinct structural features are difficult to define, the cytokine-inducing potential of 1-7 seemingly decreased
with increasing polarity. To investigate this phenomenon, the testing of nanoparticles will be the subject of
prospective research.
Table. Antileishmanial activity against a panel of Leishmania amastigotes (AM) and TNF, IFNγ- and IL-6 inducing
potential of compounds 1-7 on RAW 264.7 cells (IC50 values in nM).

Compound
1
2
3
4
5
6
7
Pentostam
IFN-γ/LPS

442

AM
6.3
3.9
6.4
2.8
12.5
8.7
3.2
11.2
—

L. major
TNF IFN-γ
205
42
72
17
30
16
51
12
34
34
56
26
9
4
—
—
206
—

IL-6
33
7
6
4
6
3
3
—
10

AM
1.5
3.0
3.9
2.5
12.8
24.2
3.0
10.6
—

L. donovani
TNF IFN-γ
235
39
89
15
31
14
63
13
29
26
36
11
13
4
—
—
197
—

IL-6
26
6
7
3
6
4
4
10
—

AM
3.0
3.6
3.0
15.0
4.8
20.6
3.1
—
—

L. amazonensis
TNF IFN-γ IL-6
270
36
31
68
13
6
36
12
7
59
11
32
30
3
43
21
7
11
6
3
—
—
123
210
—
—
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